CLINICAL ROLE -
Genzyme's Lumizyme Now Indicated for Infantile-Onset Pompe Disease
FDA will no longer require Genzyme to continue the Risk Evaluation and Mitigation Strategy program.
New Study Quantifies Duchenne Caregivers' Assessment of Risk vs Reward
Caregivers give thoughts on attributes they are looking for in DMD treatment.
FDA Guidance for Expedited Programs For Serious Conditions
FDA updates guidelines to expedite the development and review of new drugs.
Efficacy and Safety of Gazyva in Chronic Lymphocytic Leukemia
2 Commerce Drive Cranbury, NJ 08512